CompletedNot Applicable

PROSpective Assessment of Post EmR Recurrence

Australia700 participantsStarted 2017-01

Plain-language summary

To prospectively validate the SERT (Sydney EMR Recurrence Tool) scoring system for adenoma recurrence rates around the endoscopic mucosal resection (EMR) scar after wide field-EMR with thermal treatment applied to the defect margin. The primary aim of the study will be to ensure the safety of this approach and there will be constant monitoring to ensure that this is the case.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All laterally spreading lesions \>= 20mm referred to the named tertiary referral centres * Must consent to involvement Exclusion Criteria: * Histology other than specified * Lesion involving the ileocaecal valve * Pregnancy: currently pregnant or attempting to become pregnant * Lactation: currently breastfeeding * Taken clopidogrel within 7 days * Taken warfarin within 5 days * Had full therapeutic dose unfractionated heparin within 6 hours * Had full therapeutic dose low molecular weight heparin (LMWH) within 12 hours * Known clotting disorder * Previous attempt at EMR of the polyp referred for resection

What they're measuring

Adenoma recurrence

Timeframe: Variable dependent on SERT score

Trial details

NCT IDNCT02957058

SponsorWestern Sydney Local Health District

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-01

View on ClinicalTrials.gov More Colonic Adenoma trials